このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers

2026年7月30日 更新者:Tuğçe Poyraz İşleyen、Bahçeşehir University

Comparison of 30-Second Sit-to-Stand Test Performance Between Individuals With Hemophilia and Healthy Peers: A Cross-Sectional Observational Study

Hemophilia is an inherited bleeding disorder characterized by recurrent musculoskeletal bleeding, particularly into joints, leading to impaired physical function and reduced functional performance. The 30-Second Sit-to-Stand Test (30STS) is a simple, reliable, and valid measure of lower extremity functional performance; however, evidence regarding its performance in individuals with hemophilia remains limited. This cross-sectional observational study aims to compare 30STS performance between adults with hemophilia and age-matched healthy controls and to investigate the relationship between 30STS performance, joint health, and activity level in individuals with hemophilia. Fifty-eight participants (29 individuals with hemophilia and 29 healthy controls) aged 18-35 years will be recruited. Participants will complete the 30STS. Individuals with hemophilia will additionally undergo joint health assessment using the Hemophilia Joint Health Score (HJHS) and activity evaluation using the Hemophilia Activities List (HAL).

調査の概要

状態

まだ募集していません

詳細な説明

Hemophilia is an inherited bleeding disorder caused by deficiency of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B), resulting in recurrent bleeding episodes. Repeated musculoskeletal bleeding, particularly hemarthrosis, may lead to progressive joint damage, reduced physical activity, muscle weakness, and impaired functional performance. Therefore, objective assessment of physical function is important for monitoring functional limitations and planning appropriate rehabilitation strategies in individuals with hemophilia.

The 30-Second Sit-to-Stand Test (30STS) is a simple, practical, and reliable performance-based assessment used to evaluate lower extremity strength, endurance, and functional mobility. Although the test is widely used in different populations, evidence regarding 30STS performance in individuals with hemophilia is limited. Comparing functional performance between individuals with hemophilia and healthy peers may provide valuable information regarding the functional impact of hemophilia and may contribute to clinical assessment approaches.

The aim of this cross-sectional observational study is to compare 30STS performance between individuals with hemophilia and age-matched healthy controls. Additionally, the study aims to investigate the relationship between 30STS performance, joint health status, and activity level in individuals with hemophilia.

A total of 58 participants aged 18-35 years will be included in the study, consisting of 29 individuals diagnosed with hemophilia A or hemophilia B and 29 age-matched healthy controls. All participants will perform the 30STS. Demographic characteristics, including age, height, and body weight, will be recorded. For participants with hemophilia, additional clinical information including hemophilia type, disease severity, bleeding history, and prophylaxis status will be collected.

Joint health status of individuals with hemophilia will be evaluated using the Hemophilia Joint Health Score (HJHS), and functional activity level will be assessed using the Hemophilia Activities List (HAL). The results of the 30STS will be compared between groups, and associations between functional performance, joint health, and activity level will be analyzed within the hemophilia group.

The findings of this study may contribute to a better understanding of lower extremity functional performance in individuals with hemophilia and may provide clinically relevant information for functional evaluation and rehabilitation planning

研究の種類

観察的

入学 (推定)

58

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

This study will include adult males aged 18-35 years with a diagnosis of hemophilia A or hemophilia B and age-matched healthy male controls. Participants with hemophilia will be recruited from the members of the Turkish Hemophilia Society. Healthy controls without hemophilia or other bleeding disorders will be recruited from the general population. A total of 58 participants, including 29 individuals with hemophilia and 29 healthy controls, are planned to be included in the study.

説明

Inclusion Criteria:

Hemophilia Group:

  • Diagnosis of hemophilia A or hemophilia B
  • Age between 18 and 35 years
  • Ability to walk independently
  • Willingness to participate in the study voluntarily

Healthy Control Group:

  • Age between 18 and 35 years
  • No history of hemophilia or other bleeding disorders
  • No history of lower extremity surgery or serious lower extremity injury within the previous 6 months
  • No neurological, rheumatological, or severe orthopedic disorders
  • Willingness to participate in the study voluntarily

Exclusion Criteria:

Hemophilia Group:

- Acute joint bleeding episode within the previous 3 months

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Hemophilia Group
Participants aged 18-35 years with a diagnosis of hemophilia A or hemophilia B.
Healthy Control Group
Age-matched healthy participants without hemophilia or other bleeding disorders.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
30-Second Sit-to-Stand Test Performance
時間枠:Baseline assessment (single assessment visit)
The primary outcome of this study is the performance on the 30-Second Sit-to-Stand Test (30STS). The test evaluates lower extremity functional performance by recording the number of correctly completed sit-to-stand repetitions within 30 seconds. The test will be performed once under standardized conditions in both the hemophilia group and healthy control group. Number of complete sit-to-stand repetitions performed from a standard chair within 30 seconds. Scores range from 0 to no fixed maximum, with higher scores indicating better lower extremity functional performance and muscle endurance.
Baseline assessment (single assessment visit)

二次結果の測定

結果測定
メジャーの説明
時間枠
Joint Health Status Assessed by Hemophilia Joint Health Score (HJHS)
時間枠:Baseline assessment (single assessment visit)
Joint health status will be assessed in participants with hemophilia using the Hemophilia Joint Health Score (HJHS). The HJHS evaluates hemophilic arthropathy-related findings including swelling, muscle atrophy, crepitus, range of motion loss, and pain in target joints. Total HJHS score ranges from 0 to 124; lower scores indicate better joint health and higher scores indicate greater joint impairment.
Baseline assessment (single assessment visit)
Hemophilia Activities List (HAL)
時間枠:Baseline assessment (single assessment visit)
Functional activity level in participants with hemophilia will be assessed using the Hemophilia Activities List (HAL), a patient-reported outcome measure evaluating limitations in daily activities and participation. The total score ranges from 0 to 100, with higher scores indicating better functional ability and fewer activity limitations.
Baseline assessment (single assessment visit)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Tığçe Poyraz İşleyen、Bahçeşehir University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2026年9月15日

研究の完了 (推定)

2026年9月15日

試験登録日

最初に提出

2026年7月27日

QC基準を満たした最初の提出物

2026年7月27日

最初の投稿 (実際)

2026年7月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年7月31日

QC基準を満たした最後の更新が送信されました

2026年7月30日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be shared because there is no current plan to make individual-level data available to other researchers.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する